Breast cancer cells were shown to upregulate ErbB3 via multiple mechanisms to escape pharmacological EGFR inhibition [31], and in lung cancer cells, autocrine activation of ErbB3 caused resistance to the EGFR-specific small molecule inhibitor Gefitinib [32]. The gene discussed is ERBB3; the disease is breast carcinoma.